FDA Approves Zepbound: A Game-Changer for Obstructive Sleep Apnea and Obesity Treatment
The U.S. Food and Drug Administration (FDA) has taken a groundbreaking step in addressing obstructive sleep apnea (OSA) with the approval of Eli Lilly’s weight-loss drug, Zepbound (tirzepatide). This marks the first pharmacological treatment approved specifically for OSA in adults…